C-RAF (Phospho-Ser642) Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-C-RAF (Phospho-Ser642) antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | C-RAF (Phospho-Ser642) |
| Clone | polyclonal |
| Host Species | Rabbit |
| Reactive Species | human |
| Isotype | n/a |
| Format | epitope affinity purified |
| Size | 0.05 mL, 0.1 mL |
| Concentration | 1.0 mg/ml |
| Applications | Western Blot (WB) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | The antibody detects endogenous levels of C-RAF only when phosphorylated at serine 642. Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates |
| Immunogen | Immunogen Type: Peptide-KLH Immunogen Description: Peptide sequence around phosphorylation site of Serine 642(T-T-S(p)-P-R) derived from Human C-RAF. |
| Other Names | [C-RAF; C-Raf; CRAF; RAF-1] |
| Gene, Accession # | [C-RAF], Gene ID: 5894, NCBI: NP_002871.1, UniProt: P04049 |
| Catalog # | MBS9402624 |
| Price | $200, $255 |
| Order / More Info | C-RAF (Phospho-Ser642) Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies